目的 探討羅替高汀貼片聯(lián)合多巴絲肼片治療帕金森病的臨床療效。方法 選取2018年9月-2020年12月在鄭州市第九人民醫(yī)院就診的108例帕金森病患者作為研究對(duì)象,按照隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組,每組各54例。對(duì)照組患者口服多巴絲肼片,3次/d,首次劑量0.125 g/次,每周增加劑量0.125 g,維持劑量3次/d,0.25 g/次。治療組患者在對(duì)照組基礎(chǔ)上聯(lián)合羅替高汀貼片,1次/d,首次劑量4.5 mg/10 cm²,每周增加劑量4.5 mg/10 cm²,維持劑量每次13.5 mg/30 cm²。兩組患者連續(xù)治療3個(gè)月。觀察兩組患者的臨床療效,比較兩組患者的生活質(zhì)量、新版世界運(yùn)動(dòng)障礙病學(xué)會(huì)帕金森病綜合評(píng)價(jià)量表(MDS-UPDRS)評(píng)分和血清因子水平。結(jié)果 治療后,治療組的總有效率為94.44%,對(duì)照組的總有效率為81.48%,組間比較有明顯差異(P<0.05)。治療后,兩組的帕金森調(diào)查表(PDQ-39)評(píng)分顯著降低(P<0.05);且治療后治療組PDQ-39評(píng)分低于對(duì)照組(P<0.05)。治療后,兩組的非運(yùn)動(dòng)癥狀評(píng)分、運(yùn)動(dòng)癥狀評(píng)分、運(yùn)動(dòng)功能檢查評(píng)分、運(yùn)動(dòng)并發(fā)癥評(píng)分均顯著降低(P<0.05);治療組的非運(yùn)動(dòng)癥狀評(píng)分、運(yùn)動(dòng)癥狀評(píng)分、運(yùn)動(dòng)功能檢查評(píng)分、運(yùn)動(dòng)并發(fā)癥評(píng)分明顯低于對(duì)照組(P<0.05)。治療后,兩組的血清淀粉樣蛋白A(SAA)、白細(xì)胞介素-12(IL-12)水平顯著降低,載脂蛋白A1水平顯著升高(P<0.05);治療組SAA、IL-12水平比對(duì)照組低,載脂蛋白A1比對(duì)照組高,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 羅替高汀貼片聯(lián)合多巴絲肼片治療帕金森病的療效確切,能有效改善患者生活質(zhì)量,減輕臨床癥狀,減輕炎癥反應(yīng)。

Objective To investigate the clinical efficacy of Rotigotine Patch combined with Levodopa and Benserazide Hydrochloride Tablets in treatment of Parkinson’s disease. Methods Patients (108 cases) with Parkinson’s disease in Ninth People’s Hospital of Zhengzhou from September 2018 to December 2020 were randomly divided into control and treatment groups, and each group had 54 cases. Patients in the control group were po administered with Levodopa and Benserazide Hydrochloride Tablets, three times daily.The first dose was 0.125 g/time, the dose was increased by 0.125 g every week, and the maintenance dose was 0.25 g/time, three times daily. Patients in the treatment group were given Rotigotine Patch on the basis of the control group. The first dose was 4.5 mg/10 cm², the dose was increased by 4.5 mg/10 cm² every week, and the maintenance dose was 13.5 mg/30 cm². Patients in two groups were treated for three months. After treatment, the clinical efficacies were evaluated, and the quality of life, the MDS-UPDRS score and the serum factor levels in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.44%, the total effective rate of the control group was 81.48%, and there was a significant difference between two groups (P < 0.05). After treatment, the PDQ-39 score of two groups were significantly decreased (P < 0.05), and the PDQ-39 score of the treatment group was lower than that of the control group (P < 0.05). After treatment, the scores of non-motor symptoms, motor symptoms, motor function examination, and motor complications in two groups were significantly decreased (P < 0.05). The scores of non-motor symptoms, motor symptoms, motor function examination, and motor complications in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the serum levels of SAA and IL-12 in two groups were significantly decreased, but the level of apolipoprotein A1 in two groups significantly increased (P < 0.05). The levels of SAA and IL-12 in the treatment group were lower than those in the control group, but the apolipoprotein A1 in the treatment group was higher than that in the control group, and the difference was statistically significant (P < 0.05). Conclusion Rotigotine Patch combined with Levodopa and Benserazide Hydrochloride Tablets in treatment of Parkinson’s disease, can effectively improve the quality of life of patients, reduce clinical symptoms and reduce inflammatory reaction.

R971

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（2018020864）